b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">29790816</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>04</Month>\n            <Day>24</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>04</Month>\n            <Day>24</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1366-5928</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>49</Volume>\n                    <Issue>5</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>May</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Xenobiotica; the fate of foreign compounds in biological systems</Title>\n                <ISOAbbreviation>Xenobiotica</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>The effect of elevated \xce\xb1<sub>1</sub>-acid glycoprotein on the pharmacokinetics of TAK-272 (SCO-272), an orally active renin inhibitor, in rats.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>584-590</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1080/00498254.2018.1480817</ELocationID>\n            <Abstract>\n                <AbstractText>The pharmacokinetics of TAK-272 (SCO-272), an orally active renin inhibitor, was investigated in rats with subcutaneously injected turpentine oil, which was an inflammation animal model. Following intravenous administration of TAK-272 to the turpentine-treated rats, the systemic clearance and volume of distribution decreased with the elevated plasma \xce\xb1<sub>1</sub>-acid glycoprotein (AGP) levels. The elevated plasma AGP levels were negatively correlated with the plasma unbound fraction of TAK-272 in the rats. Although the AUCs of total TAK-272 in the turpentine-treated rats were higher than those in the control rats after intravenous and oral administration, those of unbound TAK-272, which seem to directly contribute to the pharmacological effect and safety, were nearly equal between the turpentine-treated and control rats in the respective dose routes. TAK-272 has been shown to primarily bind to AGP in the human plasma. These results strongly suggested that the pharmacokinetic of TAK-272 in humans would also be affected by the variation in the plasma AGP levels and should be discussed with not only the total concentrations but also the unbound concentrations in the clinical trial for patients with elevated plasma AGP levels.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Ebihara</LastName>\n                    <ForeName>Takuya</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Drug Metabolism and Pharmacokinetics Research Laboratories, Pharmaceutical Research Division , Takeda Pharmaceutical Company Limited , Kanagawa , Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Shimizu</LastName>\n                    <ForeName>Hisao</ForeName>\n                    <Initials>H</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Drug Metabolism and Pharmacokinetics Research Laboratories, Pharmaceutical Research Division , Takeda Pharmaceutical Company Limited , Kanagawa , Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Yamamoto</LastName>\n                    <ForeName>Masami</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Drug Metabolism and Pharmacokinetics Research Laboratories, Pharmaceutical Research Division , Takeda Pharmaceutical Company Limited , Kanagawa , Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Higuchi</LastName>\n                    <ForeName>Tomoaki</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Drug Metabolism and Pharmacokinetics Research Laboratories, Pharmaceutical Research Division , Takeda Pharmaceutical Company Limited , Kanagawa , Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Jinno</LastName>\n                    <ForeName>Fumihiro</ForeName>\n                    <Initials>F</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Drug Metabolism and Pharmacokinetics Research Laboratories, Pharmaceutical Research Division , Takeda Pharmaceutical Company Limited , Kanagawa , Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Tagawa</LastName>\n                    <ForeName>Yoshihiko</ForeName>\n                    <Initials>Y</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>a Drug Metabolism and Pharmacokinetics Research Laboratories, Pharmaceutical Research Division , Takeda Pharmaceutical Company Limited , Kanagawa , Japan.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2018</Year>\n                <Month>06</Month>\n                <Day>25</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>England</Country>\n            <MedlineTA>Xenobiotica</MedlineTA>\n            <NlmUniqueID>1306665</NlmUniqueID>\n            <ISSNLinking>0049-8254</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D001562">Benzimidazoles</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D009025">Morpholines</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D009961">Orosomucoid</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D010880">Piperidines</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>1NE31CW68S</RegistryNumber>\n                <NameOfSubstance UI="C000628410">imarikiren hydrochloride</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 3.4.23.15</RegistryNumber>\n                <NameOfSubstance UI="D012083">Renin</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>XJ6RUH0O4G</RegistryNumber>\n                <NameOfSubstance UI="D014425">Turpentine</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D001562" MajorTopicYN="N">Benzimidazoles</DescriptorName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009025" MajorTopicYN="N">Morpholines</DescriptorName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009961" MajorTopicYN="N">Orosomucoid</DescriptorName>\n                <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName>\n                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="Y">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D012083" MajorTopicYN="N">Renin</DescriptorName>\n                <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D014425" MajorTopicYN="N">Turpentine</DescriptorName>\n                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">Pharmacokinetics</Keyword>\n            <Keyword MajorTopicYN="N">TAK-272</Keyword>\n            <Keyword MajorTopicYN="N">plasma protein binding</Keyword>\n            <Keyword MajorTopicYN="N">\xce\xb1-acid glycoprotein</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2018</Year>\n                <Month>5</Month>\n                <Day>24</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>4</Month>\n                <Day>25</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2018</Year>\n                <Month>5</Month>\n                <Day>24</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">29790816</ArticleId>\n            <ArticleId IdType="doi">10.1080/00498254.2018.1480817</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'